Drugs / ABS-201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07317544 | Dec 2025 → Jul 2028 expected | androgenetic alopecia | Absci Pty Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABS-201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07317544 ↗ |
| Modality | Monoclonal antibody | “ABS-201 is an IgG1 monoclonal antibody” NCT07317544 ↗ |
| Route | Intravenous | “Single Intra-venous dose of active study drug or placebo in Healthy Volunteers” NCT07317544 ↗ |